Intra-cellular therapies reports third quarter 2024 financial results, provides corporate update and raises 2024 caplyta sales guidance

Caplyta q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase

ITCI Ratings Summary

ITCI Quant Ranking